Literature DB >> 9544842

A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes.

B Jeschke1, K Uhl, B Weist, D Schröder, T Meitinger, C Döhlemann, H P Vosberg.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetically and clinically heterogeneous myocardial disease that is in most cases familial and transmitted in a dominant fashion. The most frequently affected gene codes for the cardiac (ventricular) beta-myosin heavy chain. We have investigated the genetic cause of an isolated case of HCM, which was marked by an extremely severe phenotype and a very early age of onset. HCM is normally not a disease of small children. The proband was a boy who had suffered cardiac arrest at the age of 6.5 years (resuscitation by cardioconversion). Upon screening of the beta-myosin heavy chain gene as a candidate, two missense mutations, one in exon 19 (Arg719Trp) and a second in exon 12 (Met349Thr), were identified. The Arg719Trp mutation was de novo, as it was not found in the parents. In contrast, the Met349Thr mutation was inherited through the maternal grandmother. Six family members were carriers of this mutation but only the proband was clinically affected. Segregation and molecular analysis allowed us to assign the Met349Thr mutation to the maternal and the Arg719Trp de novo mutation to the paternal beta-myosin allele. Thus, the patient has no normal myosin. We interpret these findings in terms of compound heterozygosity of a dominant (Arg719Trp) and a recessive (Met349Thr) mutation. Whereas a single mutated Arg719Trp allele would be sufficient to cause HCM, the concurrent Met349Thr mutation alone does not apparently induce the disease. Nevertheless, it conceivably contributes to the particularly severe phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544842     DOI: 10.1007/s004390050695

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  15 in total

Review 1.  Molecular genetics of cardiomyopathies.

Authors:  G Shah; R Roberts
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

Review 2.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 3.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

4.  On predictors of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

Review 5.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

Review 6.  [Genetic causes of hypertrophic cardiomyopathy].

Authors:  H P Vosberg
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 7.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

8.  Molecular genetic and functional characterization implicate muscle-restricted coiled-coil gene (MURC) as a causal gene for familial dilated cardiomyopathy.

Authors:  Gabriela Rodriguez; Tomomi Ueyama; Takehiro Ogata; Grazyna Czernuszewicz; Yanli Tan; Gerald W Dorn; Roberta Bogaev; Katsuya Amano; Hidemasa Oh; Hiroaki Matsubara; James T Willerson; Ali J Marian
Journal:  Circ Cardiovasc Genet       Date:  2011-06-03

9.  Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy.

Authors:  P Richard; R Isnard; L Carrier; O Dubourg; Y Donatien; B Mathieu; G Bonne; F Gary; P Charron; M Hagege; M Komajda; K Schwartz; B Hainque
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

10.  Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?

Authors:  Hans-Peter Vosberg
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.